Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer

被引：13
|
作者：
Heigener, David F. [1 ,2 ,3 ]
Kerr, Keith M. [4 ]
Laing, Gavin M. [4 ]
Mok, Tony S. K. [5 ]
Moiseyenko, Fedor V. [6 ,7 ]
Reck, Martin [3 ,8 ,9 ]
机构：
[1] Helios Klinikum Schleswig, Dept Pulmonol, Schleswig, Germany
[2] Univ Kiel, Kiel, Germany
[3] Airway Res Ctr North German Ctr Lung Res DZL, Grosshansdorf, Germany
[4] Aberdeen Royal Infirm, Dept Pathol, Aberdeen, Scotland
[5] Chinese Univ Hong Kong, Fac Med, Hong Kong, Peoples R China
[6] Inst Oncol NN Petrov St Petersburg, Pesochny, Russia
[7] St Petersburg City Canc Ctr, St Petersburg, Russia
[8] LungenClin Grosshansdorf, Grosshansdorf, Germany
[9] Univ Lubeck, Lubeck, Germany
来源：
CLINICAL CANCER RESEARCH | 2019年 / 25卷 / 16期
关键词：
PLATINUM-BASED CHEMOTHERAPY; DABRAFENIB PLUS TRAMETINIB; OPEN-LABEL; EGFR MUTATIONS; INTERNATIONAL ASSOCIATION; PHASE-III; AFATINIB; MULTICENTER; CRIZOTINIB; GEFITINIB;
D O I：
10.1158/1078-0432.CCR-18-1894
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Metastatic non-small-cell lung cancer is still a devastating disease; however, treatment options have diversified dramatically in the past two decades. From unselected platinum-based chemotherapy for all patients, several different treatment groups have evolved, that is, those with "druggable" targets, those with a promising immune signature, and those without any predicting factors outlined in this article. Challenge includes the intersections between these groups and the optimal treatment path. These issues will be addressed in this review.
引用
收藏
页码：4881 / 4887
页数：7
相关论文
共 50 条
  • [1] First-line treatment for advanced non-small-cell lung cancer
    Laskin, Janessa J.
    Sandler, Alan B.
    ONCOLOGY-NEW YORK, 2005, 19 (13): : 1671 - 1676
  • [2] Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Gettinger, Scott
    Rizvi, Naiyer A.
    Chow, Laura Q.
    Borghaei, Hossein
    Brahmer, Julie
    Ready, Neal
    Gerber, David E.
    Shepherd, Frances A.
    Antonia, Scott
    Goldman, JonathanW.
    Juergens, Rosalyn A.
    Laurie, Scott A.
    Nathan, Faith E.
    Shen, Yun
    Harbison, Christopher T.
    Hellmann, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2980 - +
  • [3] First-line immunotherapy in advanced non-small-cell lung cancer
    Noronha, Vanita
    Mehta, Prashant
    Malik, Prabhat Singh
    Patel, Amol
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 461 - 462
  • [4] Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer
    Socinski, M. A.
    CURRENT ONCOLOGY, 2014, 21 (05) : E691 - E703
  • [5] Erlotinib in the first-line treatment of non-small-cell lung cancer
    D'Arcangelo, Manolo
    Cappuzzo, Federico
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (05) : 523 - 533
  • [6] First-line treatment of advanced ALK-positive non-small-cell lung cancer
    Gandhi, Shipra
    Chen, Hongbin
    Zhao, Yujie
    Dy, Grace K.
    LUNG CANCER-TARGETS AND THERAPY, 2015, 6 : 71 - 82
  • [7] Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
    Liam, Chong-Kin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S62 - S66
  • [8] EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
    Kao, Hsiang-Fong
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    FUTURE ONCOLOGY, 2013, 9 (07) : 991 - 1003
  • [9] Oxaliplatin in First-line Therapy for Advanced Non-Small-Cell Lung Cancer
    Raez, Luis E.
    Kobina, Svetlana
    Santos, Edgardo S.
    CLINICAL LUNG CANCER, 2010, 11 (01) : 18 - 24
  • [10] Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer
    Laktionov, K.
    Smolin, A.
    Stroyakovskiy, D.
    Moiseenko, V.
    Dvorkin, M.
    Andabekov, T.
    Cheng, Y.
    Liu, B.
    Kozlov, V.
    Odintsova, S.
    Dvoretsky, S.
    Mochalova, A.
    Urda, M.
    Yi, T.
    Li, X.
    Laszlo, U.
    Mueller, V.
    Bogos, K.
    Fadeeva, N.
    Musaev, G.
    Liu, Q.
    Kirtbaya, D.
    Shi, J.
    Gladkov, O.
    Narimanov, M.
    Semiglazova, T.
    Khasanova, A.
    Chovanec, J.
    Andrasina, I
    Szabova, A.
    Rosinska, O.
    Sudekova, D.
    Zsolt, P. -s.
    Ran, F.
    Sun, M.
    Jiang, O.
    Chen, R.
    Zhao, E.
    Liu, C.
    Tan, W.
    Pirmagomedov, A.
    Poddubskaya, E.
    Kislov, N.
    Shumskaya, I.
    Sorokina, I.
    Zinkina-Orikhan, A.
    Linkova, Yu.
    Fogt, S.
    Liaptseva, D.
    Siliutina, A.
    EUROPEAN JOURNAL OF CANCER, 2025, 217
12345